CONTACT US
Home > Inhibitors/Agonists> > Cytochrome P450 2C9
329978-01-0-Cytochrome P450 2C9 Cytochrome P450 2C9

Cytochrome P450 2C9

For research use only. Not for therapeutic Use.

  • CAT Number: I025444
  • CAS Number: 329978-01-0
  • Molecular Formula: C37H40FeN5O7S
  • Molecular Weight: 754.66
  • Purity: 98%
Inquiry Now
Related Small Molecules: Selnoflast     ABT-239     Malvidin-3-glucoside chloride    

Cytochrome P450 2C9 is a cytochrome P-450 subtype that has specificity for acidic XENOBIOTICS. It oxidizes a broad range of important clinical drugs that fall under the categories of NONSTEROIDAL ANTI-INFLAMMATORY AGENTS; HYPOGLYCEMIC AGENTS; ANTCOAGULANTS; and DIURETICS.


Catalog Number I025444
CAS Number 329978-01-0
Synonyms

Cytochrome P450 2C9; Cyp2C9; Cytochrome P 450 2C9; Human cytochrome P450 2C9; Cytochrome P 450 MP-4; S-Mephenytoin 4-hydroxylase;

Molecular Formula C37H40FeN5O7S
Purity 98%
Solubility Soluble in DMSO
Appearance Solid powder
Storage Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
IUPAC Name iron(III) (R)-2-amino-2-carboxyethane-1-thiolate 2,18-bis(2-carboxyethyl)-3,7,12,17-tetramethyl-8,13-divinylporphyrin-21,22-diide hydrate
InChI InChI=1S/C34H34N4O4.C3H7NO2S.Fe.H2O/c1-7-21-17(3)25-13-26-19(5)23(9-11-33(39)40)31(37-26)16-32-24(10-12-34(41)42)20(6)28(38-32)15-30-22(8-2)18(4)27(36-30)14-29(21)35-25;4-2(1-7)3(5)6;;/h7-8,13-16H,1-2,9-12H2,3-6H3,(H4,35,36,37,38,39,40,41,42);2,7H,1,4H2,(H,5,6);;1H2/q;;+3;/p-3/b25-13-,26-13-,27-14-,28-15-,29-14-,30-15-,31-16-,32-16-;;;/t;2-;;/m.0../s1
InChIKey JXTUVEVPOSTTCZ-BCZCOZCKSA-K
SMILES CC1=C(c(cc(n2)c(CCC(O)=O)c(C)c2cc([n-]3)c(C)c(C=C)c3c4)[n-]c1cc5c(C=C)c(C)c4n5)CCC(O)=O.N[C@H](C(O)=O)C[S-].O.[Fe+3]
Reference

1: Wang Z, Sun W, Huang CK, Wang L, Xia MM, Cui X, Hu GX, Wang ZS. Inhibitory effects of curcumin on activity of cytochrome P450 2C9 enzyme in human and 2C11 in rat liver microsomes. Drug Dev Ind Pharm. 2015 Apr;41(4):613-6. doi: 10.3109/03639045.2014.886697. Epub 2014 Feb 12. PubMed PMID: 24517573.
2: Wei X, Zhang D, Dou X, Niu N, Huang W, Bai J, Zhang G. Elevated 14,15- epoxyeicosatrienoic acid by increasing of cytochrome P450 2C8, 2C9 and 2J2 and decreasing of soluble epoxide hydrolase associated with aggressiveness of human breast cancer. BMC Cancer. 2014 Nov 18;14:841. doi: 10.1186/1471-2407-14-841. PubMed PMID: 25406731; PubMed Central PMCID: PMC4247238.
3: Wang H, Ren L, He Y, Wei Y, Chen Z, Yang W, Fu Y, Xu X, Fu W, Hu G, Lou W. Association between cytochrome P450 2C9 gene polymorphisms and colorectal cancer susceptibility: evidence from 16 case-control studies. Tumour Biol. 2014 May;35(5):4317-22. doi: 10.1007/s13277-013-1566-5. Epub 2014 Jan 11. PubMed PMID: 24414392.
4: Van Booven D, Marsh S, McLeod H, Carrillo MW, Sangkuhl K, Klein TE, Altman RB. Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics. 2010 Apr;20(4):277-81. doi: 10.1097/FPC.0b013e3283349e84. Review. PubMed PMID: 20150829; PubMed Central PMCID: PMC3201766.
5: Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013 Apr;138(1):103-41. doi: 10.1016/j.pharmthera.2012.12.007. Epub 2013 Jan 16. Review. PubMed PMID: 23333322.
6: Iwasaki K, Kitsugi Y, Ikeda K, Yoshikawa T, Hosaka S, Uehara S, Uno Y, Utoh M, Yamazaki H. In vivo individual variations in pharmacokinetics of efavirenz in cynomolgus monkeys genotyped for cytochrome P450 2C9. Biopharm Drug Dispos. 2016 Sep;37(6):379-83. doi: 10.1002/bdd.2021. PubMed PMID: 27417918.
7: Attia TZ, Yamashita T, Hammad MA, Hayasaki A, Sato T, Miyamoto M, Yasuhara Y, Nakamura T, Kagawa Y, Tsujino H, Omar MA, Abdelmageed OH, Derayea SM, Uno T. Effect of cytochrome P450 2C19 and 2C9 amino acid residues 72 and 241 on metabolism of tricyclic antidepressant drugs. Chem Pharm Bull (Tokyo). 2014;62(2):176-81. PubMed PMID: 24492587.
8: Yamaori S, Koeda K, Kushihara M, Hada Y, Yamamoto I, Watanabe K. Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity. Drug Metab Pharmacokinet. 2012;27(3):294-300. Epub 2011 Dec 13. PubMed PMID: 22166891.
9: Franken CC, Kaiser AF, Krüger JC, Overbeck K, Mügge A, Neubauer H. Cytochrome P450 2B6 and 2C9 genotype polymorphism–a possible cause of prasugrel low responsiveness. Thromb Haemost. 2013 Jul;110(1):131-40. doi: 10.1160/TH13-01-0021. Epub 2013 Apr 25. PubMed PMID: 23615745.
10: Xu X, Qian J, Yu J, Zhang Y, Liu S. Cytochrome P450 enzyme functionalized-quantum dots as photocatalysts for drug metabolism. Chem Commun (Camb). 2014 Jul 21;50(57):7607-10. doi: 10.1039/c4cc01717j. PubMed PMID: 24821498.
11: Preissner SC, Hoffmann MF, Preissner R, Dunkel M, Gewiess A, Preissner S. Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. PLoS One. 2013 Dec 10;8(12):e82562. doi: 10.1371/journal.pone.0082562. eCollection 2013. Review. PubMed PMID: 24340040; PubMed Central PMCID: PMC3858335.
12: Chang Q, Berdyshev E, Cao D, Bogaard JD, White JJ, Chen S, Shah R, Mu W, Grantner R, Bettis S, Grassi MA. Cytochrome P450 2C epoxygenases mediate photochemical stress-induced death of photoreceptors. J Biol Chem. 2014 Mar 21;289(12):8337-52. doi: 10.1074/jbc.M113.507152. Epub 2014 Feb 11. PubMed PMID: 24519941; PubMed Central PMCID: PMC3961660.
13: Reynald RL, Sansen S, Stout CD, Johnson EF. Structural characterization of human cytochrome P450 2C19: active site differences between P450s 2C8, 2C9, and 2C19. J Biol Chem. 2012 Dec 28;287(53):44581-91. doi: 10.1074/jbc.M112.424895. Epub 2012 Nov 1. PubMed PMID: 23118231; PubMed Central PMCID: PMC3531772.
14: Zhou SF, Zhou ZW, Yang LP, Cai JP. Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Review. PubMed PMID: 19515014.
15: Rydberg P, Olsen L. Predicting drug metabolism by cytochrome P450 2C9: comparison with the 2D6 and 3A4 isoforms. ChemMedChem. 2012 Jul;7(7):1202-9. doi: 10.1002/cmdc.201200160. Epub 2012 May 16. PubMed PMID: 22593031.
16: Xu X, Wei W, Huang M, Yao L, Liu S. Electrochemically driven drug metabolism via cytochrome P450 2C9 isozyme microsomes with cytochrome P450 reductase and indium tin oxide nanoparticle composites. Chem Commun (Camb). 2012 Aug 14;48(63):7802-4. doi: 10.1039/c2cc33575a. Epub 2012 Jun 28. PubMed PMID: 22743353.
17: Hosoi Y, Uno Y, Murayama N, Fujino H, Shukuya M, Iwasaki K, Shimizu M, Utoh M, Yamazaki H. Monkey liver cytochrome P450 2C19 is involved in R- and S-warfarin 7-hydroxylation. Biochem Pharmacol. 2012 Dec 15;84(12):1691-5. doi: 10.1016/j.bcp.2012.09.026. Epub 2012 Oct 3. PubMed PMID: 23041648.
18: Niwa T, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull. 2005 Sep;28(9):1805-8. PubMed PMID: 16141567.
19: Liu X, Hu L, Ge G, Yang B, Ning J, Sun S, Yang L, Pors K, Gu J. Quantitative analysis of cytochrome P450 isoforms in human liver microsomes by the combination of proteomics and chemical probe-based assay. Proteomics. 2014 Aug;14(16):1943-51. doi: 10.1002/pmic.201400025. Epub 2014 Jul 14. PubMed PMID: 24920405.
20: Lee SY, Lee JY, Kang W, Kwon KI, Park SK, Oh SJ, Ma JY, Kim SK. Cytochrome P450-mediated herb-drug interaction potential of Galgeun-tang. Food Chem Toxicol. 2013 Jan;51:343-9. doi: 10.1016/j.fct.2012.10.012. Epub 2012 Oct 25. PubMed PMID: 23104244.

Request a Quote